Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Food Effects on Pharmacokinetics Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants

NCT04641260
View directory record Official record
Conditions
Healthy Subjects
Interventions
Fezolinetant
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Jul 24, 2026, 8:29 AM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

NCT03359733
View directory record Official record
Conditions
Lymphoma, Malignant, Advanced Solid Neoplasms
Interventions
TAK-659
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • Detroit, Michigan • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

NCT06568458
View directory record Official record
Conditions
Healthy Participants
Interventions
Nintedanib, BMS 986278
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

NCT01264380
View directory record Official record
Conditions
Malignant Melanoma
Interventions
RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 24, 2026, 8:29 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

NCT02120976
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
JTT-252 or Placebo, JTT-252
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 24, 2026, 8:29 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

NCT03490162
View directory record Official record
Conditions
Malaria
Interventions
DM1157, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

NCT05391022
View directory record Official record
Conditions
Advanced Malignancies, Solid Tumor, Hematological Malignancy
Interventions
Pelabresib
Drug
Lead sponsor
Constellation Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Canton, Ohio • Gettysburg, Pennsylvania • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

NCT05630677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

NCT07404137
View directory record Official record
Conditions
Healthy Participants
Interventions
Zibotentan/Dapagliflozin FDC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib

NCT04800614
View directory record Official record
Conditions
Healthy Adults
Interventions
sitravatinib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)

NCT06619314
View directory record Official record
Conditions
Healthy
Interventions
Calderasib, PPI
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

A Study of RO5045337 in Patients With Solid Tumors

NCT01164033
View directory record Official record
Conditions
Neoplasms
Interventions
RO5045337
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Scottsdale, Arizona • Kansas City, Kansas • Kensignton, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3484356 in Healthy Female Participants

NCT04840888
View directory record Official record
Conditions
Healthy
Interventions
LY3484356, Omeprazole, Itraconazole, Carbamazepine, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects

NCT05232461
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PrimeC-ER 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg
Drug
Lead sponsor
NeuroSense Therapeutics Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

NCT00939757
View directory record Official record
Conditions
Healthy, Pharmacokinetics of Mirabegron
Interventions
mirabegron
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers

NCT03897413
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-888711, Calcium Antacid
Drug · Dietary Supplement
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers

NCT04705922
View directory record Official record
Conditions
Healthy
Interventions
TT-00420 Capsule, TT-00420 Tablet
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

NCT07329972
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

NCT03502902
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HEC 68498, Placebo
Drug
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

NCT02184429
View directory record Official record
Conditions
Healthy
Interventions
PF-06669571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Food Effect of K-877 in Healthy Adult Volunteers

NCT04742218
View directory record Official record
Conditions
Healthy
Interventions
K-877
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

NCT01821079
View directory record Official record
Conditions
Healthy
Interventions
PF-05175157
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Jul 24, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)

NCT06772805
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 24, 2026, 8:29 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers

NCT03567694
View directory record Official record
Conditions
Asthma
Interventions
HA115, Placebo
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 24, 2026, 8:29 AM EDT